DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $237,732 | -37.3% | 943 | -34.0% | 0.11% | -25.2% |
| Q4 2022 | $379,130 | +63.4% | 1,428 | +58.7% | 0.15% | +10.5% |
| Q3 2022 | $232,000 | -10.4% | 900 | -12.0% | 0.13% | -7.6% |
| Q2 2022 | $259,000 | -44.1% | 1,023 | -35.2% | 0.14% | +4.3% |
| Q1 2022 | $463,000 | -22.4% | 1,578 | -13.1% | 0.14% | -13.2% |
| Q4 2021 | $597,000 | +18.0% | 1,816 | +9.3% | 0.16% | +43.2% |
| Q3 2021 | $506,000 | +32.8% | 1,662 | +17.2% | 0.11% | +54.2% |
| Q2 2021 | $381,000 | +14.1% | 1,418 | -4.5% | 0.07% | +10.8% |
| Q1 2021 | $334,000 | +8.1% | 1,485 | +6.8% | 0.06% | +18.2% |
| Q4 2020 | $309,000 | -10.2% | 1,391 | -13.0% | 0.06% | -22.5% |
| Q3 2020 | $344,000 | +32.8% | 1,599 | +9.4% | 0.07% | +26.8% |
| Q2 2020 | $259,000 | -12.5% | 1,462 | -24.2% | 0.06% | -5.1% |
| Q4 2019 | $296,000 | -41.5% | 1,928 | -45.0% | 0.06% | -47.3% |
| Q3 2019 | $506,000 | +10.5% | 3,504 | +9.3% | 0.11% | -13.2% |
| Q2 2019 | $458,000 | +301.8% | 3,205 | +178.9% | 0.13% | +344.8% |
| Q4 2017 | $114,000 | – | 1,149 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |